Financial Metrics Exploration: Understanding Adma Biologics Inc (ADMA) Through Ratios

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Adma Biologics Inc (NASDAQ: ADMA) was $11.47 for the day, up 0.61% from the previous closing price of $11.40. In other words, the price has increased by $0.61 from its previous closing price. On the day, 1.58 million shares were traded. ADMA stock price reached its highest trading level at $11.49 during the session, while it also had its lowest trading level at $11.175.

Ratios:

Our analysis of ADMA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 58.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 164.84. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 5.21. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.

On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.

Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 14 ’24 when Grossman Adam S sold 100,000 shares for $10.72 per share. The transaction valued at 1,071,980 led to the insider holds 2,081,475 shares of the business.

ELMS STEVE sold 411,829 shares of ADMA for $2,503,920 on Mar 19 ’24. The Director now owns 2,115,671 shares after completing the transaction at $6.08 per share. On Mar 18 ’24, another insider, ELMS STEVE, who serves as the Director of the company, sold 49,887 shares for $6.01 each. As a result, the insider received 299,821 and left with 2,527,500 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 2598578688 and an Enterprise Value of 2694683136. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.39 while its Price-to-Book (P/B) ratio in mrq is 17.30. Its current Enterprise Value per Revenue stands at 9.516 whereas that against EBITDA is 48.579.

Stock Price History:

Over the past 52 weeks, ADMA has reached a high of $11.68, while it has fallen to a 52-week low of $3.06. The 50-Day Moving Average of the stock is 25.17%, while the 200-Day Moving Average is calculated to be 98.21%.

Shares Statistics:

ADMA traded an average of 2.91M shares per day over the past three months and 3630850 shares per day over the past ten days. A total of 226.06M shares are outstanding, with a floating share count of 224.02M. Insiders hold about 3.36% of the company’s shares, while institutions hold 75.55% stake in the company. Shares short for ADMA as of 1718323200 were 9440492 with a Short Ratio of 3.24, compared to 1715731200 on 8442938. Therefore, it implies a Short% of Shares Outstanding of 9440492 and a Short% of Float of 4.2.

Most Popular